First Hawaiian Bank Has $1.77 Million Position in AstraZeneca PLC (NASDAQ:AZN)

First Hawaiian Bank boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 6.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 24,086 shares of the company’s stock after acquiring an additional 1,557 shares during the quarter. First Hawaiian Bank’s holdings in AstraZeneca were worth $1,770,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Banque Transatlantique SA bought a new stake in AstraZeneca in the fourth quarter valued at approximately $26,000. Confluence Investment Management LLC bought a new stake in shares of AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. bought a new stake in shares of AstraZeneca during the fourth quarter worth $29,000. CoreCap Advisors LLC increased its position in shares of AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after acquiring an additional 155 shares in the last quarter. Finally, Crews Bank & Trust bought a new position in AstraZeneca in the fourth quarter valued at $55,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an “overweight” rating for the company. UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Finally, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, AstraZeneca currently has an average rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Performance

Shares of AZN stock opened at $70.87 on Friday. The company has a fifty day moving average price of $69.39 and a two-hundred day moving average price of $69.62. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. The stock has a market cap of $219.79 billion, a P/E ratio of 31.36, a P/E/G ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. AstraZeneca’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.06 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.